PERRIGO COMPANY PLC

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Market Capitalization 1.8289 B
Employee 8 379
Founded N/A
CEO Murray S. Kessler
Website www.perrigo.com
Headquarter Ireland
FIGI N/A
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

1.83 B Market capitalization

Price to earnings ratio

-57.18

Price to sales ratio

0.7

Dividends per share

0.29

Dividend yield %

9.07

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.